EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tracer‐based lipidomics enables the discovery of disease‐specific candidate biomarkers in mitochondrial β‐oxidation disorders

Marit Schwantje iD, Signe Mosegaard iD, Suzan J G Knottnerus, Jan Bert van Klinken, Ronald J Wanders, Henk van Lenthe, Jill Hermans, Lodewijk IJlst, Simone W Denis, Yorrick R J Jaspers, Sabine A Fuchs iD, Riekelt H Houtkooper iD und 2 weitere

The FASEB Journal · 2024

DOI: 10.1096/fj.202302163r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Marit Schwantje und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Lipidomics, Mitochondrial Diseases, Muscular Diseases, Mitochondrial Myopathies. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Metakids/PNO Zorg, Independent Research Fund Denmark, NWO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carnitine derivatives of disease‐specific acyl‐CoAs are the diagnostic hallmark for long‐chain fatty acid β‐oxidation disorders (lcFAOD), including carnitine shuttle deficiencies, very‐long‐chain acyl‐CoA dehydrogenase deficiency (VLCADD), long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (MPTD). The exact consequence of accumulating lcFAO‐intermediates and their influence on cellular lipid homeostasis is, however, still unknown. To investigate the fate and cellular effects of the accumulating lcFAO‐intermediates and to explore the presence of disease‐specific markers, we used tracer‐based lipidomics with deuterium‐labeled oleic acid (D9‐C18:1) in lcFAOD patient‐derived fibroblasts. In line with previous studies, we observed a trend towards neutral lipid accumulation in lcFAOD. In addition, we detected a direct connection between the chain length and patterns of (un)saturation of accumulating acylcarnitines and the various enzyme deficiencies. Our results also identified two disease‐specific candidate biomarkers. Lysophosphatidylcholine(14:1) (LPC(14:1)) was specifically increased in severe VLCADD compared to mild VLCADD and control samples. This was confirmed in plasma samples showing an inverse correlation with enzyme activity, which was better than the classic diagnostic marker C14:1‐carnitine. The second candidate biomarker was an unknown lipid class, which we identified as S‐(3‐hydroxyacyl)cysteamines. We hypothesized that these were degradation products of the CoA moiety of accumulating 3‐hydroxyacyl‐CoAs. S‐(3‐hydroxyacyl)cysteamines were significantly increased in LCHADD compared to controls and other lcFAOD, including MTPD. Our findings suggest extensive alternative lipid metabolism in lcFAOD and confirm that lcFAOD accumulate neutral lipid species. In addition, we present two disease‐specific candidate biomarkers for VLCADD and LCHADD, that may have significant relevance for disease diagnosis, prognosis, and monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipidomicsMitochondrial DiseasesMuscular DiseasesMitochondrial MyopathiesRhabdomyolysisLipid Metabolism, Inborn ErrorsCardiomyopathiesCongenital Bone Marrow Failure SyndromesNervous System DiseasesHumansCarnitineCysteamineLipidsMitochondrial Trifunctional Protein

Stichwörter der Autor:innen

biomarkersinborn errorslipid metabolismlipid metabolism disorderslipidomicslipolysis and fatty acidslysophospholipidsmitochondria

Substanzen

CarnitineCysteamineLipidsMitochondrial Trifunctional Protein

Autor:innen und Institutionen

  • Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Metabolic Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Amsterdam Gastroenterology, Endocrinology, and Metabolism, Amsterdam, the Netherlands.
  • Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
  • Emma Center for Personalized Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
  • Core Facility Metabolomics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: Marit Schwantje, Signe Mosegaard, Sabine A Fuchs, Riekelt H Houtkooper, Sacha Ferdinandusse, Frédéric M Vaz

Förderung

  • Metakids/PNO Zorg
  • Independent Research Fund Denmark
  • NWO
  • Danmarks Frie Forskningsfond
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Schwantje, M., Mosegaard, S., Knottnerus, S. J. G., van Klinken, J. B., Wanders, R. J., van Lenthe, H., Hermans, J., IJlst, L., Denis, S. W., Jaspers, Y. R. J., Fuchs, S. A., Houtkooper, R. H., Ferdinandusse, S., & Vaz, F. M. (2024). Tracer‐based lipidomics enables the discovery of disease‐specific candidate biomarkers in mitochondrial β‐oxidation disorders. The FASEB Journal. https://doi.org/10.1096/fj.202302163r

Vancouver

Schwantje M, Mosegaard S, Knottnerus SJG, van Klinken JB, Wanders RJ, van Lenthe H, et al. Tracer‐based lipidomics enables the discovery of disease‐specific candidate biomarkers in mitochondrial β‐oxidation disorders. The FASEB Journal. 2024. doi:10.1096/fj.202302163r

BibTeX
@article{Schwantje2024,
  author = {Schwantje, Marit and Mosegaard, Signe and Knottnerus, Suzan J G and van Klinken, Jan Bert and Wanders, Ronald J and van Lenthe, Henk and Hermans, Jill and IJlst, Lodewijk and Denis, Simone W and Jaspers, Yorrick R J and Fuchs, Sabine A and Houtkooper, Riekelt H and Ferdinandusse, Sacha and Vaz, Frédéric M},
  title = {Tracer‐based lipidomics enables the discovery of disease‐specific candidate biomarkers in mitochondrial β‐oxidation disorders},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202302163r}
}
Kostenlos starten →